Cimavax-EGF in Combination with First-Line Chemotherapy in III Stage NSCLC

被引：0
|
作者：
Neninger, E. [1 ]
Caceres, H. [1 ]
Camacho, K. [2 ]
Hernandez, M. [3 ]
Santiesteban, E. [2 ]
Del Castillo, C. [4 ]
Menendez, Y. [4 ]
Gonzalez, B. [5 ]
机构：
[1] Hermanos Ameijeiras Hosp, Clin Oncol, Havana, Cuba
[2] Jose Ramon Lopez Hosp, Clin Oncol, Matanzas, Cuba
[3] Mol Immunol Ctr, Havana, Cuba
[4] Hermanos Ameijeiras Hosp, Radiotherapy, Havana, Cuba
[5] Ramon Lopez Tabranes Hosp, Matanzas, Cuba
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Cimavax Egf vaccine; IIIa NSCLC; immunogenicity;
D O I：
10.1016/j.jtho.2019.08.1435
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-92
引用
收藏
页码：S676 / S677
页数：2
相关论文
共 50 条
  • [31] Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC
    Dhillon, Sohita
    Syed, Yahiya Y.
    TARGETED ONCOLOGY, 2019, 14 (06) : 759 - 768
  • [32] Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC
    Sohita Dhillon
    Yahiya Y. Syed
    Targeted Oncology, 2019, 14 : 759 - 768
  • [33] First-line chemotherapy
    Kaye, S
    KEY ADVANCES IN THE CLINICAL MANAGEMENT OF OVARIAN CANCER, 2003, : 33 - 37
  • [34] Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC
    Chen, Ping
    Li, Yinfeng
    Jing, Xiaomei
    Chen, Jing
    Chen, Shimei
    Yang, Qing
    LUNG CANCER, 2022, 174 : 157 - 164
  • [35] Sparing Treatment with Cytostatics for Patients with advanced NSCLC Dual Immunotherapy and Chemotherapy Combination is approved as First-line Therapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 70 - 70
  • [36] A Multicenter, Randomized, Phase 3 Trial of Penpulimab in Combination With Anlotinib or Chemotherapy as First-Line Treatment in Advanced NSCLC
    Han, B.
    Chen, J.
    Xie, Q.
    Yao, W.
    Shi, H.
    Zhao, Y.
    Song, W.
    Jin, X.
    Wang, Z.
    Li, B.
    Xia, Y.
    Jiao, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S650 - S650
  • [37] A phase III study of erlotinib as maintenance therapy in NSCLC to delay progression following first-line chemotherapy (SATURN)
    Cappuzzo, F.
    Coudert, B.
    Wierzbicki, R.
    Park, K.
    Custers, F.
    Curbera, G. A.
    Giaccone, G.
    Hilbe, W.
    Klingelschmitt, G.
    Ciuleanu, T.
    EJC SUPPLEMENTS, 2009, 7 (02): : 553 - 553
  • [38] Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer
    Moy, Ryan H.
    Fernandes, Gustavo Dos Santos
    Jonsson, Philip
    Chou, Joanne F.
    Basunia, Azfar
    Ku, Geoffrey Y.
    Chalasani, Sree B.
    Boyar, Michelle S.
    Goldberg, Zoe
    Desai, Avni M.
    Gabler, Amelia
    Berger, Michael F.
    Tang, Laura H.
    Hechtman, Jaclyn F.
    Kelsen, David P.
    Schattner, Mark
    Ilson, David H.
    Solit, David B.
    Taylor, Barry S.
    Schultz, Nikolaus
    Capanu, Marinela
    Janjigian, Yelena Y.
    ONCOLOGIST, 2020, 25 (01): : E68 - E74
  • [39] START2: Tecemotide in unresectable stage III NSCLC after first-line concurrent chemoradiotherapy.
    Ramalingam, Sureah S.
    Mitchell, Paul
    Vansteenkiste, Johan F.
    Debus, Juergen
    Curran, Walter J.
    Socinski, Mark A.
    Heiwig, Christoph
    Falk, Martin H.
    Butts, Charles Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer
    Reesink, Daan
    van Melick, Harm H. E.
    van der Nat, Paul
    Los, Maartje
    Horenblas, Simon
    van de Garde, Ewoudt M. W.
    Santeon MIBC Study Grp
    WORLD JOURNAL OF UROLOGY, 2023, 41 (06) : 1551 - 1562
12345